Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Study of NCI Supplied Cabozantinib (NSC #761968) Versus Weekly Paclitaxel (NSC #673089) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Brief Summary: This randomized phase II trial studies how well giving cabozantinib-s-malate or paclitaxel works in treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cavity cancer. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether cabozantinib-s-malate or paclitaxel is more effective at treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cavity cancer.


Options:
A: Arm Label: Arm I (cabozantinib-s-malate); Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib S-malate, Other: Laboratory Biomarker Analysis | Arm Label: Arm II (paclitaxel); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Drug: Paclitaxel | Intervention Type: DRUG; Name: Cabozantinib S-malate; Assigned to Arm(s): Arm I (cabozantinib-s-malate) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (cabozantinib-s-malate), Arm II (paclitaxel) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm II (paclitaxel)
B: Arm Label: Aflibercept 2.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Arm Label: Aflibercept 4.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept 4.0 mg/kg | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept 2.0 mg/kg
C: Arm Label: non platinum based chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: stealth liposomal doxorubicin, Drug: carboplatin, Drug: paclitaxel, Drug: Topotecan, Drug: Gemcitabine | Arm Label: platinum based chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: stealth liposomal doxorubicin, Drug: carboplatin, Drug: paclitaxel, Drug: Topotecan, Drug: Gemcitabine | Intervention Type: DRUG; Name: stealth liposomal doxorubicin; Assigned to Arm(s): non platinum based chemotherapy, platinum based chemotherapy | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): non platinum based chemotherapy, platinum based chemotherapy | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): non platinum based chemotherapy, platinum based chemotherapy | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): non platinum based chemotherapy, platinum based chemotherapy | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): non platinum based chemotherapy, platinum based chemotherapy
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olaparib, Drug: paclitaxel, Drug: Drug: carboplatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel, Drug: carboplatin | Intervention Type: DRUG; Name: olaparib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Drug: carboplatin; Assigned to Arm(s): 1

Answer: A